An Overview of the Orphan Medicines Market in Turkey

Value in Health Regional Issues

Volumn 4, Issue 1, 2014, Pages 47-52

  Koçkaya, Güvenç ^a   Wertheimer, Albert I ^b   Kilic, Pelin ^c   Tanyeri, Pelin ^d   Mert Vural, I ^c   Akbulat, Akif ^c   Artiran, Guven ^c   Kerman, Saim ^c  

^a Polar Health Economics and Policy Consultancy Firm   (Turkey)

^b TEMPLE UNIVERSITY   (United States)

^c Turkish Medicines and Medical Devices Agency   (Turkey)

^d SAKARYA UNIVERSITY   (Turkey)

Author keywords

Early access; Orphan drugs; Turkey

Indexed keywords

AGALSIDASE BETA; ANTINEOPLASTIC AGENT; AZASITIDINE; BOSENTAN; BUSULFAN; DARASIROX; DASATINIB; DEFERASIROX; EVEROLIMUS; IMATINIB; LARONIDASE; LENALIDOMIDE; MIGLUSTAT; NILOTINIB; ORPHAN DRUG; PEGVISOMANT; SILDENAFIL; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; ARSENIC TRIOXIDE; BETAINE; CARGLUMIC ACID; CLOFARABINE; ECULIZUMAB; IBUPROFEN; IDURONATE 2 SULFATASE; MITOTANE; NELARABINE; RECOMBINANT SOMATOMEDIN C; UNINDEXED DRUG;

ARTICLE; DRUG COST; DRUG INDICATION; DRUG MARKETING; DRUG USE; EXTRACTION; GOVERNMENT; HUMAN; LICENSING; PRIORITY JOURNAL; REIMBURSEMENT; SYSTEMATIC REVIEW; TURKEY (REPUBLIC); DRUG CLASSIFICATION; EUROPEAN MEDICINES AGENCY; GOVERNMENT REGULATION; HEALTH CARE ORGANIZATION; PHARMACIST; RARE DISEASE;

EID: 84904917381     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2014.06.009     Document Type: Article

References (22)

1. Analysis Group. Innovation in the biopharmaceutical pipeline: a multidimensional view. Available from:. [Accessed June 16, 2014]. http://www.phrma.org/sites/default/files/pdf/2013innovationinthebiopharmaceuticalpipeline-analysisgroupfinal.pdf.
2. National Institutes of Health, Office of Rare Diseases Research. Rare diseases and related terms. Available from:. [Accessed October 7, 2011]. http://www.rarediseases.info.nih.gov.
3. Sardana D., Zhu C., Zhang M., et al. Drug repositioning for orphan diseases. Brief Bioinform 2011, 12:346-356.
4. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. J Eur Comm 2000, European Commission, (L18/1).
5. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011, 6:42.
6. Moliner A.M. Creating a European Union framework for actions in the field of rare diseases. Adv Exp Med Biol 2010, 686:457-473.
7. Code of Federal Regulations Title 21: Part 316. Orphan drug regulations: proposed rule. Fed Reg 1991, 56:3338-3351. US Food and Drug Administration.
8. Pariser A.R., Xu K., Milto J., Coté T.R. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials. Discov Med 2011, 11:367-375.
9. Braun M.M., Farag-El-Massah S., Xu K., Coté T.R. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010, 9:519-522.
10. Taruscio D., Vittozzi L., Stefanov R. National plans and strategies on rare diseases in Europe. Adv Exp Med Biol 2010, 686:475-491.
11. Wellman-Labadie O., Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?. Health Policy 2010, 95:216-228.
12. Liu B.C., He L., He G., He Y. A cross-national comparative study of orphan drug policies in the Untied States, the European Union and Japan: towards a made-in-China orphan drug policy. J Public Health Policy 2010, 31:407-420.
13. Tauruscio D., Capozzoli F., Frank C. Rare diseases and orphan drugs. Ann Ist Super Sanita 2011, 47:83-93.
14. Owen A., Sprinks J., Meehan A., et al. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. J Med Econ 2008, 11:235-243.
15. OrphaNet. List of substances. Available from:. [Accessed October 7, 2011]. http://www.orpha.net/consor/cgi-bin/Drugs_ListSubstance.php?lng=EN.
16. European Medicine Agency. European public assessment reports. Available from:. [Accessed October 7, 2011]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jspmid=WC0b01ac058001d125.
17. Butlen-Ducuing F., Riviere F., Aarum S., Llinares-Garcia J. European Medicines Agency support mechanisms fostering orphan drug development. Drug News Perspect 2010, 23:71-81.
18. Kockaya G., Kilic P. Pharmaceutical policies and market access in Turkey. ISPOR CONNECTIONS March/April 2012, 8-10.
19. Social Security Institution (Sosyal Güvenlik Kurumu). Guideline for the dossier for the application to the reimbursement commission. 2008. Available from:. [Accessed October 7, 2011]. http://www.edak.org.tr/www/ekler/odemeusulesaslari_klavuz.pdf.
20. Koçkaya G., Polat M., Vural I.M., et al. Off-label and unlicensed oncology medicine use in Turkey: a retrospective analysis of computer records of the Turkish Ministry of Health. J Pharm Health Serv Res 2011, 2:53-57.
21. Picavet E, Dooms M, Cassiman D, Simoens S. PHP28 drugs for rare diseases: influence of orphan designation status on price. Value Health 2011;14:A338.
22. Kilic P, Kockaya G, Yemsen O, et al. Orphan drug regulations in Turkey. J Pharm Health Serv Res 2013;4:151-3.